Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone + lidocaine is a combination drug consisting of dexamethasone, a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties, and lidocaine, an amide-type local anesthetic that provides rapid pain relief by blocking sodium channels in neuronal membranes. This combination is used to provide both immediate analgesia (from lidocaine) and longer-term anti-inflammatory effects (from dexamethasone). It has been studied for use in perioperative pain management (e.g., reducing injection pain during propofol administration), oral inflammatory conditions such as mucositis or lichen planus, and as an adjuvant in regional anesthesia[2][5][7]. Dexamethasone acts primarily via activation of the glucocorticoid receptor to inhibit pro-inflammatory gene expression and reduce leukocyte migration; lidocaine blocks voltage-gated sodium channels to prevent nerve impulse conduction[9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + lidocaine.